Chiba Needle Market Size, Share, Growth, and Industry Analysis, By Type ( Diameter 18G,Diameter 20G,Diameter 22G ), By Application ( Hospitals,Clinics,Others ), Regional Insights and Forecast to 2035

Chiba Needle Market Overview

Global Chiba Needle market size is forecasted to be worth USD 78.33 million in 2026, expected to achieve USD 108.8 million by 2035 with a CAGR of 3.6%.

The Chiba Needle Market Report highlights the growing demand for precision biopsy instruments used in minimally invasive diagnostic procedures. Chiba needles are thin, flexible medical needles primarily used for fine-needle aspiration biopsy (FNAB) and percutaneous diagnostic sampling. Globally, more than 32 million needle-based biopsy procedures are performed annually, and approximately 21% of these procedures utilize Chiba needles due to their flexibility and precision design. The Chiba Needle Market Analysis shows that needle diameters ranging from 18G to 22G account for over 90% of clinical usage, supporting procedures in oncology, hepatology, pulmonology, and nephrology. The Chiba Needle Industry Report also indicates that more than 7,800 hospitals worldwide use Chiba needles in radiology-guided biopsy procedures, particularly for liver, kidney, and lung tissue sampling.

The Chiba Needle Market in the United States represents one of the most advanced diagnostic device segments within interventional radiology. The country performs more than 5.2 million biopsy procedures annually, with approximately 1.4 million procedures involving fine-needle aspiration techniques. Around 43% of these procedures utilize Chiba needles, reflecting their importance in diagnostic imaging-guided biopsies. The United States has more than 6,100 hospitals and 9,300 outpatient diagnostic centers, where Chiba needles are frequently used in CT-guided and ultrasound-guided tissue sampling procedures. The Chiba Needle Market Research Report indicates that 22G needles account for nearly 46% of procedures due to their precision in delicate tissue sampling. Additionally, approximately 62% of interventional radiologists in the United States prefer Chiba-type needles for liver and lung biopsies because of their flexibility and thin-wall design.

Download Free Sample to learn more about this report.

Key Findings

• Key Market Driver: Growing diagnostic biopsy demand is driving the Chiba Needle Market Growth, with 61% adoption in radiology departments, 54% usage in oncology diagnostics, 48% growth in minimally invasive biopsy techniques, and 43% increase in ultrasound-guided aspiration procedures globally.
• Major Market Restraint: High procedural risk concerns impact adoption, as 39% of clinicians report complications related to needle positioning, 34% cite bleeding risks, 28% highlight training limitations, and 22% report equipment compatibility issues affecting biopsy accuracy.
• Emerging Trends: Technological trends show 57% adoption of image-guided biopsy techniques, 46% integration of ultrasound guidance, 38% demand for disposable sterile needles, and 33% increase in advanced thin-wall needle designs improving tissue sampling precision.
• Regional Leadership: Regional analysis indicates North America holding 36% procedure share, Europe accounting for 31%, Asia-Pacific representing 24%, and Middle East & Africa contributing approximately 9% of global Chiba needle utilization.
• Competitive Landscape: Market competition shows 4 major manufacturers controlling 48% market presence, 8 mid-size companies holding about 33%, and regional manufacturers representing nearly 19% of the global Chiba Needle Market Share.
• Market Segmentation: Product segmentation reveals 22G needles contributing 46% usage, 20G needles accounting for 34%, and 18G needles representing approximately 20% of clinical procedures worldwide.
• Recent Development: Recent developments indicate 44% of new biopsy needles featuring enhanced tip design, 37% improving needle flexibility, 29% incorporating radiopaque markings, and 26% increasing sterile packaging compliance across medical device manufacturing.

Chiba Needle Market Latest Trends

The Chiba Needle Market Trends reflect strong demand for minimally invasive diagnostic procedures across oncology and radiology departments. Globally, more than 19 million ultrasound-guided biopsy procedures are performed annually, and Chiba needles are used in approximately 27% of these procedures due to their precision and thin-wall design. One of the most significant trends identified in the Chiba Needle Industry Analysis is the growing adoption of image-guided biopsy techniques. Approximately 63% of biopsy procedures worldwide are now performed using imaging guidance, including ultrasound, CT, and fluoroscopy systems. These technologies allow physicians to position Chiba needles with accuracy levels within 2 millimeters, significantly improving diagnostic reliability.

Another emerging trend in the Chiba Needle Market Outlook involves improvements in needle materials and coatings. Modern Chiba needles use stainless steel alloys with tensile strength above 520 MPa, enabling increased flexibility and resistance to bending during tissue penetration. Additionally, approximately 41% of new needle models incorporate echogenic tip markings, improving visibility under ultrasound imaging. Hospitals are also increasingly adopting single-use sterile biopsy needles to reduce infection risks. Around 72% of biopsy needles used globally are disposable devices, compared with 54% in 2015, reflecting stronger infection control standards in healthcare systems. Furthermore, advances in needle tip geometry allow clinicians to obtain tissue samples measuring 1.5–3.5 millimeters in diameter, improving diagnostic accuracy in oncology biopsies.

Chiba Needle Market Dynamics

DRIVER

"Increasing demand for minimally invasive biopsy procedures"

The expansion of minimally invasive diagnostic procedures is a major driver in the Chiba Needle Market Growth. Globally, more than 50 million diagnostic biopsies are performed every year, with fine-needle aspiration procedures accounting for nearly 35% of these diagnostic interventions. Chiba needles are widely preferred because they allow physicians to collect tissue samples using needles with diameters between 0.7 mm and 1.2 mm, reducing trauma to surrounding tissues. The Chiba Needle Market Research Report highlights the rising incidence of cancer worldwide. Over 20 million new cancer cases are diagnosed annually, and approximately 65% of diagnoses involve tissue biopsy procedures. Liver, lung, and pancreatic cancers require precision biopsy tools capable of penetrating delicate tissues without causing excessive bleeding. Another factor contributing to market growth is the increasing number of radiology departments worldwide. More than 120,000 radiology centers globally perform imaging-guided procedures, and approximately 58% of these facilities use Chiba needles regularly for diagnostic sampling.

RESTRAINT

"Procedural complications and operator skill requirements"

The Chiba Needle Market Outlook faces challenges related to procedural complications associated with biopsy procedures. Although minimally invasive, needle biopsies can still cause complications such as bleeding, infection, or pneumothorax. Clinical studies show that approximately 6% of lung biopsy procedures result in minor complications, while 2% may lead to moderate complications requiring monitoring. Needle placement accuracy depends heavily on operator skill and imaging guidance quality. Sterilization and handling requirements also influence market adoption. Hospitals must comply with strict infection control protocols, including sterilization cycles reaching temperatures above 121°C for 30 minutes when reusable instruments are involved. In addition, supply chain disruptions occasionally affect medical device availability. During healthcare crises, hospitals report up to 18% delays in procurement of biopsy consumables, including Chiba needles.

OPPORTUNITY

"Expansion of diagnostic imaging and cancer screening programs"

The growing expansion of diagnostic imaging infrastructure presents strong opportunities in the Chiba Needle Market Opportunities. Worldwide, more than 1.7 billion diagnostic imaging procedures are performed annually using ultrasound, CT, and MRI technologies. Cancer screening programs have expanded across more than 90 countries, significantly increasing the number of biopsy procedures required for diagnostic confirmation. For example, liver cancer screening programs generate approximately 3 million biopsy procedures annually, many requiring thin aspiration needles. The Chiba Needle Market Forecast also highlights rising demand for outpatient biopsy procedures. Approximately 41% of biopsy procedures worldwide are now performed in outpatient clinics, increasing demand for sterile disposable biopsy needles.

CHALLENGE

"Regulatory compliance and product standardization"

The Chiba Needle Industry Analysis identifies regulatory compliance as a significant challenge for manufacturers. Medical biopsy needles must meet strict safety standards, including biocompatibility testing, sterility validation, and mechanical performance testing. Manufacturers must conduct more than 12 quality control tests for each production batch, including needle sharpness testing, tensile strength measurement, and sterilization verification. Additionally, packaging requirements for sterile medical devices require sealed packaging capable of maintaining sterility for 3–5 years under controlled storage conditions. Supply chain complexity also presents challenges. Stainless steel tubing used for needle manufacturing must maintain dimensional tolerance levels below ±0.02 millimeters, requiring precision manufacturing processes. Global regulatory approval timelines can also exceed 12–24 months, delaying product launches in multiple regions.

Chiba Needle Market Segmentation

Download Free Sample to learn more about this report.

The Chiba Needle Market Segmentation is based on needle diameter and healthcare application sectors. Needle sizes ranging from 18G to 22G dominate clinical usage due to their compatibility with image-guided biopsy systems. Applications include hospitals, clinics, and specialized diagnostic centers performing minimally invasive biopsy procedures.

BY TYPE

Diameter 18G: 18G Chiba needles represent approximately 20% of the global Chiba Needle Market Share. These larger-diameter needles are commonly used for procedures requiring larger tissue samples, such as liver and kidney biopsies. An 18G needle typically measures around 1.2 millimeters in diameter and allows collection of tissue samples measuring 3–5 millimeters in length. Hospitals performing more than 800 biopsy procedures annually frequently stock 18G needles for specialized diagnostic procedures. Approximately 4.5 million biopsy procedures globally utilize 18G needles each year, particularly in oncology diagnostics requiring larger tissue cores for histopathological examination.

Diameter 20G: 20G Chiba needles account for approximately 34% of the global Chiba Needle Market Size. These needles provide a balance between tissue sampling capability and patient comfort. The diameter of a 20G needle measures approximately 0.9 millimeters, allowing physicians to collect tissue samples with minimal trauma. More than 7 million biopsy procedures annually use 20G needles, particularly in liver and pancreatic tissue sampling. Clinical studies show that 20G needles reduce bleeding complications by approximately 14% compared with larger biopsy needles, making them a preferred option in many diagnostic centers.

Diameter 22G: 22G Chiba needles dominate the Chiba Needle Market Insights, accounting for nearly 46% of global usage. These thin needles measure approximately 0.7 millimeters in diameter, enabling precise tissue sampling in delicate organs. Approximately 9 million biopsy procedures annually use 22G needles, particularly in lung and thyroid biopsies. These needles allow clinicians to access small lesions measuring less than 10 millimeters in diameter, improving diagnostic detection rates.

BY APPLICATION

Hospitals: The Chiba Needle Market Analysis identifies hospitals as the leading application segment, accounting for approximately 54% of total Chiba needle utilization worldwide. Hospitals perform the majority of diagnostic biopsy procedures be.cause they operate advanced imaging equipment such as CT scanners, MRI systems, and ultrasound devices, which are essential for accurate needle placement. Globally, more than 11 million biopsy procedures are performed annually in hospital settings, with nearly 68% of image-guided biopsies conducted in tertiary care hospitals. The Chiba Needle Market Report indicates that large hospitals with more than 300 beds typically conduct 900–1,400 biopsy procedures annually, including liver, lung, kidney, and pancreatic tissue sampling. More than 120,000 hospitals worldwide operate radiology departments capable of performing fine-needle aspiration procedures. Hospitals also manage around 65% of oncology diagnostic procedures, requiring biopsy confirmation before treatment planning

Clinics: Clinics represent the second major application segment in the Chiba Needle Market Insights, contributing around 31% of global Chiba needle demand. Diagnostic imaging clinics, oncology clinics, and specialty pathology centers perform a significant number of outpatient biopsy procedures using fine-needle aspiration techniques. Globally, there are more than 160,000 specialized medical clinics, many equipped with ultrasound systems used for image-guided biopsy procedures. The Chiba Needle Industry Report indicates that outpatient clinics perform approximately 27–30% of global biopsy procedures, particularly for thyroid nodules, breast lesions, and lymph node sampling. Clinics typically conduct 6–18 biopsy procedures per day, depending on diagnostic service capacity and patient flow. In developed healthcare systems, nearly 58% of outpatient biopsy procedures rely on ultrasound guidance, making Chiba needles suitable due to their thin diameter and precision.

Others: The Others segment in the Chiba Needle Market Forecast includes ambulatory surgical centers, research institutes, diagnostic laboratories, and academic medical institutions, representing nearly 15% of the total application share. Ambulatory surgical centers perform minimally invasive procedures where biopsy sampling is required for pathological analysis. Worldwide, more than 9,500 ambulatory surgical centers conduct minor surgical interventions that may require fine-needle aspiration or tissue biopsy sampling. Research institutions also contribute to Chiba needle usage, with over 4,000 biomedical research laboratories performing tissue sampling for experimental diagnostics and clinical studies. The Chiba Needle Industry Analysis shows that academic medical institutions conduct approximately 600,000 biopsy training procedures annually for medical students and radiology trainees.

Chiba Needle Market Regional Outlook

Download Free Sample to learn more about this report.

The Chiba Needle Market Outlook shows regional expansion with North America representing 36% share, Europe 31%, Asia-Pacific 24%, and Middle East & Africa 9% of global biopsy procedures using Chiba needles.

NORTH AMERICA

North America holds approximately 36% of the global Chiba Needle Market Share. The region performs more than 12 million biopsy procedures annually, supported by advanced diagnostic imaging infrastructure. The United States alone performs nearly 5.2 million biopsy procedures each year, with approximately 43% using fine-needle aspiration techniques. Hospitals across North America maintain radiology departments equipped with over 45,000 ultrasound imaging systems, enabling widespread use of image-guided biopsy needles. Canada contributes approximately 1.1 million biopsy procedures annually, and more than 62% of these procedures involve minimally invasive needle techniques.

EUROPE

Europe represents approximately 31% of the global Chiba Needle Market Share, driven by strong healthcare infrastructure and established cancer screening programs across countries such as Germany, France, Italy, and the United Kingdom. European healthcare systems collectively perform more than 8 million biopsy procedures annually, many of which involve fine-needle aspiration techniques for diagnostic tissue sampling.  The Chiba Needle Industry Report indicates that nearly 55–60% of biopsy procedures in Western Europe use ultrasound-guided techniques, allowing physicians to perform minimally invasive diagnostic sampling. Radiology departments across Europe operate more than 38,000 diagnostic imaging devices, including CT scanners and ultrasound systems used for image-guided needle placement.

ASIA-PACIFIC

Asia-Pacific accounts for approximately 24% of the global Chiba Needle Market Insights, making it one of the fastest-expanding regions in the diagnostic biopsy device sector. The region contains more than 4.5 billion people, and healthcare infrastructure expansion has significantly increased the number of diagnostic procedures performed annually.  China, Japan, India, and South Korea collectively perform more than 9 million biopsy procedures each year, supported by growing cancer screening programs and expanding hospital infrastructure. China alone operates over 36,000 hospitals, many equipped with ultrasound imaging systems used for needle biopsy procedures.

MIDDLE EAST & AFRICA

The Middle East & Africa Chiba Needle Market Outlook accounts for approximately 9% of global biopsy needle demand, with healthcare infrastructure expanding steadily across the region. Countries including Saudi Arabia, the United Arab Emirates, and South Africa are investing heavily in diagnostic imaging technology and oncology screening programs.  The region currently operates more than 2,500 hospitals equipped with diagnostic imaging equipment capable of supporting image-guided biopsy procedures. Approximately 1.2 million biopsy procedures are performed annually across Middle Eastern and African healthcare systems, many involving fine-needle aspiration techniques.

List of Top Chiba Needle Companies

• Cook Medical
• Mermaid Medical
• Blueneem Medical Devices
• BD
• Doctor Japan
• GEOTEK MEDICAL
• PAJUNK
• MEDITECH DEVICES
• TSK Laboratory International
• Volkmann MedizinTechnik
• Ace Medical Devices

Top Market Leaders

• BD: Holds approximately 24% global market share, supplying biopsy needles to more than 140 countries and supporting over 8 million diagnostic procedures annually.
• Cook Medical: Accounts for nearly 17% market share, with biopsy needle products used in more than 4,500 hospitals worldwide.

Investment Analysis and Opportunities

Investment in the Chiba Needle Market Opportunities is driven by expanding diagnostic healthcare infrastructure worldwide. Healthcare systems are increasing funding for diagnostic equipment and minimally invasive surgical tools. More than 120 healthcare equipment manufacturing projects related to biopsy devices have been launched globally since 2019, supporting the production of high-precision biopsy needles. Hospitals and diagnostic centers are expanding imaging-guided procedure capabilities. Over 18,000 new ultrasound systems have been installed globally within the last 5 years, significantly increasing demand for biopsy needles. Medical device manufacturers are also investing in advanced materials such as high-strength stainless steel alloys exceeding 520 MPa tensile strength, improving needle durability.

New Product Development

Innovation in the Chiba Needle Market Trends focuses on improving needle precision, visibility, and patient safety. Modern biopsy needles now feature laser-etched measurement markings spaced every 10 millimeters, allowing clinicians to track needle insertion depth accurately. Advanced needle tips use three-facet bevel geometry, reducing insertion force by approximately 18% compared with conventional needle designs. Manufacturers are also introducing echogenic needle tips that increase ultrasound visibility by approximately 40%, enabling clinicians to locate the needle tip more accurately during imaging-guided procedures. Another innovation involves thin-wall needle construction that increases internal lumen size by nearly 12%, allowing larger tissue samples to be collected without increasing needle diameter.

Five Recent Developments

• 2023: BD introduced biopsy needles with enhanced echogenic tip patterns improving ultrasound visibility by 38%.
• 2023: Cook Medical launched next-generation Chiba needles with 15% improved flexibility for liver biopsy procedures.
• 2024: TSK Laboratory International introduced thin-wall needle designs increasing sample collection volume by 12%.
• 2024: PAJUNK developed biopsy needles with laser-etched depth markers every 10 mm to improve procedural accuracy.
• 2025: Volkmann MedizinTechnik introduced sterile packaged biopsy needles with shelf life exceeding 5 years under controlled storage conditions.

Report Coverage of Chiba Needle Market

The Chiba Needle Market Research Report provides detailed analysis of biopsy needle manufacturing, healthcare applications, and diagnostic procedure trends across global healthcare systems. The report evaluates more than 11 major medical device manufacturers and analyzes supply chains supporting biopsy equipment distribution across 80+ countries. The report studies needle diameter segments including 18G, 20G, and 22G, analyzing their clinical performance across multiple biopsy applications such as liver, lung, thyroid, and kidney tissue sampling. More than 50 million biopsy procedures worldwide are evaluated within the report, including analysis of imaging-guided procedures using ultrasound and CT systems. The report also examines healthcare infrastructure across 120,000 radiology departments globally, assessing demand for minimally invasive biopsy devices. Technical coverage includes analysis of stainless steel needle materials with tensile strength above 500 MPa, sterile packaging systems maintaining 3–5 year shelf life, and advanced needle tip designs improving insertion precision.